Aquestive Therapeutics (NASDAQ: AQST) revenue
Aquestive Therapeutics reported revenue of $44.5m for fiscal 2025, 22.6% less than in fiscal 2024 ($57.6m). Since fiscal 2017 its revenue has fallen by 33.4%, an average decline of 5.0% a year.
Aquestive Therapeutics's best year of the last 9 was fiscal 2018. The biggest drop was in fiscal 2025, −22.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $44.5m | −22.6% | −$71.1m | −159.5% |
| 2024 | $57.6m | +13.8% | −$30.8m | −53.5% |
| 2023 | $50.6m | +6.1% | −$15.1m | −29.9% |
| 2022 | $47.7m | −6.2% | −$42.1m | −88.2% |
| 2021 | $50.8m | +10.9% | −$34.7m | −68.2% |
| 2020 | $45.8m | −12.8% | −$42.9m | −93.6% |
| 2019 | $52.6m | −22.0% | −$52.7m | −100.1% |
| 2018 | $67.4m | +0.8% | −$48.9m | −72.6% |
| 2017 | $66.9m | — | −$0.1m | −0.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Aquestive Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Aquestive Therapeutics ranks 333rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Aquestive Therapeutics, −22.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 331st | TriSalus Life Sciences | $45.2m | 53.4% |
| 332nd | Fennec Pharmaceuticals | $44.6m | −6.1% |
| 333rd | Aquestive Therapeutics | $44.5m | −22.6% |
| 334th | Wave Life Sciences | $42.7m | −60.5% |
| 335th | Coherus Oncology | $42.2m | 59.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Aquestive Therapeutics
- How much revenue did Aquestive Therapeutics make in fiscal 2025?
- Aquestive Therapeutics reported revenue of $44.5m for fiscal 2025, compared with $57.6m in fiscal 2024.
- How much has the revenue of Aquestive Therapeutics fallen?
- Between fiscal 2017 and fiscal 2025 it went from $66.9m to $44.5m: 33.4% less, an average decline of 5.0% a year.
- What was the best year for revenue at Aquestive Therapeutics?
- Of its last 9 fiscal years, fiscal 2018, with $67.4m.
- Where does Aquestive Therapeutics rank in its sector by revenue?
- It ranks 333rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Aquestive Therapeutics come from?
- From the annual report (Form 10-K) that Aquestive Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Aquestive Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Aquestive Therapeutics: the Aquestive Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.